Acesion Pharma starts Phase 2 trial of AP31969 in patients with atrial fibrillation
PR Newswire —
AP31969 is a novel, first-in-class, oral SK ion channel inhibitor intended for rhythm control of atrial fibrillation and has recently completed Phase 1 in healthy volunteers Phase 2 trial will assess the efficacy of AP31969 on atrial fibrillation burden and its safety profile using...